How to compare these papers
Check whether a study measures an acute hormone response or a sustained outcome. Preserve the exact molecular form, participant characteristics and sampling schedule when comparing studies.
This selected archive contains 30 notes in this topic. Groups describe study design, not a quality ranking or a complete systematic review. Publication year is the source paper year.
Questions to take to the original paper
- What material and experimental population were actually studied?
- What was compared, and which endpoint was measured?
- Were results neutral or conflicting, and what remains untested?
Human physiology study
- Kisspeptin-10 in healthy men: sustained hormone signaling over days
Kisspeptin-10 · 2026 · A small controlled physiological program examined acute, continuous and intermittent exposure schedules in healthy male volunteers.
- Kisspeptin-10 responses in women: sex-steroid context matters
Kisspeptin-10 · 2012 · A small physiological study compared short-term gonadotropin responses among women with different endogenous or contraceptive-related hormone environments.
- Kisspeptin-10 and LH pulses in men: an early physiology experiment
Kisspeptin-10 · 2011 · A small investigation measured short-term reproductive-hormone responses in healthy men.
- Kisspeptin-10: hormone responses depend on sex and cycle phase
Kisspeptin-10 · 2011 · Small volunteer groups showed why reproductive context matters when interpreting a hormone response.
- CJC-1295 proteomics: candidate biomarkers need independent validation
CJC-1295 with DAC · 2009 · A small serum-proteomics study searched for signals of GH and IGF-I activity.
- CJC-1295 and GH pulses: separating baseline secretion from pulse size
CJC-1295 with DAC · 2006 · Frequent overnight sampling explored which parts of growth-hormone secretion changed.
- Ipamorelin PK/PD: linking exposure to a short-term hormone response
Ipamorelin · 1999 · An early volunteer study modeled peptide exposure and growth-hormone measurements.
Preclinical study
- Kisspeptin-10 and cardiac fibroblasts: extracellular matrix measurements
Kisspeptin-10 · 2026 · Human cardiac fibroblast cultures were examined for glycosaminoglycans and decorin using receptor and signaling inhibitors.
- Kisspeptin forms and C6: stronger signaling can mean faster desensitization
Kisspeptin-10 · 2026 · Engineered receptor-expressing cells were used to compare kisspeptin-10, kisspeptin-54 and the synthetic C6 analog.
- Kisspeptin isoforms: stability and glucose responses diverged
Kisspeptin-10 · 2026 · Plasma stability, pancreatic-cell assays, isolated islets and mouse metabolic experiments compared three kisspeptin lengths.
- Kisspeptin-10 during ewe puberty: following endogenous changes
Kisspeptin-10 · 2026 · Ewe lambs were repeatedly sampled across development to compare circulating neuropeptides with the timing of first ovulation.
- Kisspeptin-10 in pulmonary hypertension models
Kisspeptin-10 · 2026 · A mouse pulmonary-hypertension model and hypoxic vascular smooth-muscle cells were examined for hemodynamics and mitochondrial responses.
- Ipamorelin in ferrets: weight loss and vomiting were different endpoints
Ipamorelin · 2024 · Researchers compared two ghrelin-receptor agonists using intestinal tissue and a cisplatin-exposure ferret model.
- Ipamorelin and reproductive signaling in fish
Ipamorelin · 2024 · A tilapia experiment measured feeding, testicular development, androgen-receptor expression and circulating hormones after repeated exposure.
- Ipamorelin and gastric emptying after experimental surgery
Ipamorelin · 2012 · Rats underwent abdominal surgery and intestinal manipulation, followed by gastric-emptying measurements and isolated-tissue experiments.
- Ipamorelin in postoperative rats: transit and broader recovery measures differ
Ipamorelin · 2009 · The rodent experiment preceded the later human study with nonsignificant efficacy findings.
- Long-acting CJC-1295 in GHRH-knockout mice: the model defines the claim
CJC-1295 with DAC · 2006 · The experiment investigated a specific hormone-deficient mouse model, not normal human growth.
- Ipamorelin selectivity: what the original preclinical experiments tested
Ipamorelin · 1998 · The early pharmacology paper compared hormone-release responses in cells and animals.
Clinical trial
- Tesamorelin and cognition: the between-group result was neutral
Tesamorelin · 2025 · An open-label randomized trial compared tesamorelin with standard care for six months in people with HIV and abdominal obesity.
- Tesamorelin with integrase inhibitors: a subgroup of an earlier trial
Tesamorelin · 2024 · A subgroup analysis used an existing blinded trial to examine people with HIV receiving integrase-inhibitor-based treatment.
- Tesamorelin and liver fat: a trial in people living with HIV
Tesamorelin · 2019 · A liver-fat endpoint was examined in a narrowly defined clinical population.
- Kisspeptin and brain imaging: a mechanistic human study
Kisspeptin · 2017 · Brain imaging can investigate a pathway without proving a clinical treatment effect.
- Tesamorelin: distinguishing visceral fat from liver fat
Tesamorelin · 2014 · A preliminary trial measured two different fat compartments in adults with HIV.
- Kisspeptin-54 in IVF: why the molecular form matters
Kisspeptin-54 · 2014 · An early fertility study examined kisspeptin-54 within a specialist clinical protocol.
- Ipamorelin after bowel surgery: why the nonsignificant result matters
Ipamorelin · 2014 · A phase 2 trial did not find a significant improvement in its key efficacy endpoint.
- Tesamorelin in selected adults with reduced GH secretion
Tesamorelin · 2012 · A small trial distinguished visceral fat from subcutaneous fat and clinical events.
- Tesamorelin continuation and withdrawal: interpreting a blinded extension
Tesamorelin · 2010 · A second trial used a rerandomized extension to investigate what happened after initial treatment.
- Tesamorelin in HIV-associated abdominal fat: a defined clinical population
Tesamorelin · 2007 · A controlled trial measured visceral fat by imaging rather than general weight-loss success.
- Long-acting CJC-1295: hormone measurements are not clinical outcomes
CJC-1295 with DAC · 2006 · Two early controlled trials examined exposure, growth hormone and IGF-I in healthy adults.
Mixed evidence
- Kisspeptin-10 and cerebral aneurysm models: receptor dependence
Kisspeptin-10 · 2025 · Patient biomarker observations were combined with mouse receptor-knockout experiments and human endothelial-cell assays.
These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.